Pomalidomide-15N,13C5

Pomalidomide-15N,13C5 is 15N and 13C labeled Pomalidomide (HY-10984) . Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.

Product Specifications

Product Name Alternative

CC-4047-15N,13C5

UNSPSC

12352005

Hazard Statement

H360

Target

Apoptosis; Isotope-Labeled Compounds; Ligands for E3 Ligase; Molecular Glues

Type

Isotope-Labeled Compounds

Related Pathways

Apoptosis; Others; PROTAC

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/pomalidomide-15n-13c5.html

Purity

88.33

Solubility

10 mM in DMSO

Smiles

O=C1N(C(C2=C1C=CC=C2N)=O)[13C]([13C]([15NH]3)=O)[13C][13C][13C]3=O

Molecular Formula

C8 13C5H6N2 15NO4

Molecular Weight

274.16

Precautions

H360

References & Citations

[1]Lu J, et al. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. Chem Biol. 2015 Jun 18;22 (6) :755-63.|[2]Zhu YX, et al. Molecular mechanism of action of the immune-modulatory drugs, thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013 Apr;54 (4) :683-7.|[3]Li Z, et al. Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models. PLoS One. 2013 Aug 5;8 (8) :e71754.|[4]Hernandez-Ilizaliturri FJ1, et al. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res. 2005 Aug 15;11 (16) :5984-92.|[5]Liu D, et al. Tumour necrosis factor-α inhibits hepatic lipid deposition through GSK-3β/β-catenin signaling in juvenile turbot (Scophthalmus maximus L.) . Gen Comp Endocrinol. 2016 Mar 1;228:1-8.|[6]Schafer PH, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther. 2003 Jun;305 (3) :1222-32.|[7]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.